Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 990 for:    gout
Previous Study | Return to List | Next Study

The Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03601260
Recruitment Status : Not yet recruiting
First Posted : July 26, 2018
Last Update Posted : July 26, 2018
Sponsor:
Information provided by (Responsible Party):
Hillel Yaffe Medical Center

Brief Summary:
The aim of the study is to determine the percentage of cases of acute treatment with Allopurinol in gout patients who have been previously treated.

Condition or disease Intervention/treatment Phase
Gout Drug: Allopurinol Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 700 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: To Examine the Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients as Secondary Treatment
Estimated Study Start Date : August 2018
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Gout
MedlinePlus related topics: Gout

Arm Intervention/treatment
Gout Patients
Allopurinol 100 mg-300mg/day as secondary treatment in gout patients
Drug: Allopurinol
Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol




Primary Outcome Measures :
  1. Gout patients treated with Allopurinol [ Time Frame: Six months ]
    Retrospective identification through medical records of percentage of gout patients treated with Allopurinol


Secondary Outcome Measures :
  1. Patients with contraindication to Allopurinol [ Time Frame: Six months ]
    Retrospective identification through medical records of percentage of gout patients with contraindications to Allopurinol



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Gout patients

Exclusion Criteria:

  • Pregnant women
  • Chronic renal failure
  • Patients with Allopurinal hypersensitivity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03601260


Contacts
Layout table for location contacts
Contact: Fadi Khalaila, MD 972-52-3326629 khalailaf@yahoo.com

Locations
Layout table for location information
Israel
Hillel Yaffe Medical Center Not yet recruiting
Hadera, Israel, 38100
Contact: Fadi Khalaila, MD    972-52-3326629    khalailaf@yahoo.com   
Sponsors and Collaborators
Hillel Yaffe Medical Center

Layout table for additonal information
Responsible Party: Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT03601260     History of Changes
Other Study ID Numbers: HYMC-FKH-1
First Posted: July 26, 2018    Key Record Dates
Last Update Posted: July 26, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Gout
Gout Suppressants
Arthritis
Joint Diseases
Musculoskeletal Diseases
Crystal Arthropathies
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Allopurinol
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Antirheumatic Agents
Free Radical Scavengers
Antioxidants
Protective Agents
Physiological Effects of Drugs